SCHEMBL12467754

SCHEMBL12467754

O=C(OCCOCCOCCOCCOCCOC(=O)n1ccnc1)n1ccnc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
TDP1 Q9NUW8 1/20 0.36
TBXAS1 P24557 3/20 0.35
EGLN3 Q9H6Z9 1/20 0.34
AHR P35869 1/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP24A1 Q07973 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
FAAH O00519 1/20 0.32
MGLL Q99685 1/20 0.32
TP53 P04637 2/20 0.31
TSHR P16473 2/20 0.31
HIF1A Q16665 2/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12016624 1.00 ALDH1A1 (0.36) ALDH1A1TDP1TBXAS1EGLN3AHR
SCHEMBL15465728 1.00 ALDH1A1 (0.36) ALDH1A1TDP1TBXAS1EGLN3AHR
SCHEMBL15464597 1.00 ALDH1A1 (0.36) ALDH1A1TDP1TBXAS1EGLN3AHR
SCHEMBL12016623 0.94 ALDH1A1 (0.39) ALDH1A1TDP1TBXAS1EGLN3AHR
SCHEMBL15583426 0.93 TBXAS1 (0.34) ALDH1A1TDP1TBXAS1EGLN3AHR
SCHEMBL19240712 0.92 ABCB11 (0.35) ALDH1A1TDP1TBXAS1AHRCYP24A1
SCHEMBL16214294 0.92 ABCB11 (0.35) ALDH1A1TDP1TBXAS1AHRCYP24A1
SCHEMBL12468229 0.92 TDP1 (0.32) ALDH1A1TDP1TBXAS1EGLN3AHR
SCHEMBL12414787 0.92 THRB (0.39) ALDH1A1TDP1TBXAS1AHRCYP24A1
SCHEMBL16214299 0.89 THRB (0.33) ALDH1A1TDP1TBXAS1EGLN3AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9833520-B2 Labeled, non-peptidic, multivalent integrin antagonist compounds; methods for synthesis and uses thereof THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) 2017-12-05 US disclosed
US-20140044646-A1 Labeled, Non-Peptidic, Multivalent Integrin Antagonist Compounds; Methods for Synthesis and Uses Thereof THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) 2014-02-13 US disclosed
WO-2012103328-A1 LABELED, NON- PEPTIDIC MULTIVALENT INTEGRIN ALPHA -V - BETA - 3 ANTAGONISTS, COMPOSITIONS CONTAINING THEM AND THEIR USE THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140044646-A1 Labeled, Non-Peptidic, Multivalent Integrin Antagonist Compounds; Methods for Synthesis and Uses Thereof ITGB3, ITGAV, ITGB1 ALDH1A1 2250/4885TDP1 4333/4885TBXAS1 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.